Polaris Group (TPE:6550)
11.55
+0.55 (5.00%)
Aug 26, 2026, 1:30 PM CST
Polaris Group Revenue
Polaris Group had revenue of 37.09M TWD in the quarter ending March 31, 2026, with 340.09% growth. This brings the company's revenue in the last twelve months to 69.27M, down -20.99% year-over-year. In the year 2025, Polaris Group had annual revenue of 40.60M, down -62.05%.
Revenue (ttm)
69.27M
Revenue Growth
-20.99%
P/S Ratio
136.56
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.60M | -66.40M | -62.05% |
| Dec 31, 2024 | 107.00M | 99.52M | 1,330.29% |
| Dec 31, 2023 | 7.48M | 1.04M | 16.18% |
| Dec 31, 2022 | 6.44M | -8.60M | -57.19% |
| Dec 31, 2021 | 15.04M | 5.63M | 59.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| TCM Biotech International | 701.63M |
| Tanvex BioPharma | 657.56M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 38.28M |
| Lumosa Therapeutics | 34.37M |